Mem Inst Oswaldo Cruz. 2011 Mar;106(2):177-81.

The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.

Source

Departamento de Genética, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil.

Abstract

The human immunodeficiency virus type 1 (HIV-1) protease mutation D30N is exclusively selected by the protease inhibitor (PI) nelfinavir and confers resistance to this drug. We demonstrate that D30N increases the susceptibility to saquinavir (SQV) and amprenavir in HIV-1 subtype B isolates and that the N88D mutation in a D30N background neutralizes this effect. D30N also suppresses indinavir (IDV) resistance caused by the M46I mutation. Interestingly, in patients with viruses originally containing the D30N mutation who were treated with IDV or SQV, the virus either reversed this mutation or acquired N88D, suggesting an antagonistic effect of D30N upon exposure to these PIs. These findings can improve direct salvage drug treatment in resource limited countries where subtype B is epidemiologically important and extend the value of first and second line PIs in these populations.

PMID:: 21537677; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

HIV Protease Inhibitors

LinkOut - more resources

Full Text Sources

Scientific Electronic Library Online

Medical

Resistance Testing - HIV InSite

Supplemental Content

Icon for Scientific Electronic Library Online

Save items

Related citations in PubMed

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. [Antimicrob Agents Chemother. 2...]
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, et al. Antimicrob Agents Chemother. 2004 Jun; 48(6):2159-65.
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. [AIDS Res Hum Retroviruses. 2006]
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1300-5.
Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. [HIV Med. 2003]
Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
Røge BT, Katzenstein TL, Nielsen HL, Gerstoft J. HIV Med. 2003 Jan; 4(1):38-47.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection. [Drugs. 2003]
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.
Review The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. [Antivir Ther. 2004]
Review The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D, Schapiro JM, Brenner BG, Wainberg MA. Antivir Ther. 2004 Jun; 9(3):301-14.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

The impact of the nelfinavir resistance-conferring mutation D30N on the suscepti...
The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.
Mem Inst Oswaldo Cruz. 2011 Mar ;106(2):177-81.

PubMed
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived ...
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.
J Clin Invest. 1990 Feb ;85(2):587-90.

PubMed
Mobile phone technologies improve adherence to antiretroviral treatment in a res...
Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders.
AIDS. 2011 May 15 ;25(8):1137; reply 1138-9.

PubMed
Cardiovascular effects of environmental noise: research in Sweden.
Cardiovascular effects of environmental noise: research in Sweden.
Noise Health. 2011 May-Jun ;13(52):212-6.

PubMed
Mechanisms of hypochlorite injury of target cells.
Mechanisms of hypochlorite injury of target cells.
J Clin Invest. 1990 Feb ;85(2):554-62.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: